Altria sells cigarettes and oral tobacco products, mainly in the U.S. Its brands include Marlboro, Copenhagen, Skoal, and on! nicotine pouches. Customers are adult tobacco consumers reached through distributors and retailers. [S1][S2]
Sources through 2026-09-15 · Report dated 2026-09-15
Business details
How it makes money
Revenue comes from cigarette and cigar shipments (88% of FY2025 revenue) and oral tobacco shipments (12%). Profit relies on premium pricing exceeding volume declines, with adjusted OCI margins of 64-68% in core segments. [S1][S2]
What drives results
Cigarette volume decline rate, currently 3.2% reported and 4.5% adjusted, determines revenue erosion, partly offset by 5-8% annual price increases. [S1]
Marlboro retail share near 40.5% total and 59.6% premium underpins pricing power. [S1]
Key dependencies
FDA PMTA approval governs legal marketing of new tobacco and nicotine products; MSA payments are about $3 billion annually. [S15][S20][S2]
Altria's pricing power on a shrinking cigarette base generates stable cash, but smoke-free investments have not offset volume declines; the key tension is whether cash harvest can outlast structural erosion.
Altria sells cigarettes and oral tobacco in the U.S.; Marlboro and Copenhagen anchor premium pricing, while on! provides smoke-free optionality. Revenue depends on pricing exceeding volume declines.
At $70.61, the market implies about 2% annual revenue decline, stable 45% operating margins, and flat-to-modest multiple, with little credit for smoke-free success.
A valuation model that works backward from a share price to find combinations of growth, margins, and other assumptions consistent with that price.
In this report: Used to infer what growth and margins the current $70.61 price requires.
Our assessment
Altria is a fairly valued cash-harvesting value stock: base-case intrinsic value near $73, dividend yield 6%, and expected return near 10% before multiple changes, but limited margin of safety.
Cigarette volume decline rate: current 3.2% reported, 4.5% adjusted. Each 100bp change affects intrinsic value by about $2.00 per share over five years.
Present-value estimates at 2026-09-15 using a 7.5% WACC, 1.0% terminal growth, 23% tax rate, and 1,672M diluted shares; base case blends DCF, multiples, and dividend discount model over a 5-year forecast horizon.
Scenarios are conditional estimates, not promised returns.
Bear · USD 47.5000
Bear: accelerated volume declines and promotional spending compress margins; free cash flow falls to $7-7.5B, dividend growth stalls, multiple compresses to 10x, value near $48.
Customer concentration and distributor-level revenue breakdown are not disclosed in Altria's filings. Precise stock-based compensation figures were not available from the verified data. The precise revenue contribution of NJOY and Helix International within the All Other category could not be verified.